Citadel Advisors’s IN8bio INAB Stock Holding History

Citadel Advisors’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$88.9K	Buy	+63,055	New	+$95K	﹤0.01%	12776
2025 Q4	–	Sell	-24,728	Closed	-$53.7K	–	13324
2025 Q3	$53.7K	Buy	+24,728	New	+$54.4K	﹤0.01%	12161
2025 Q2	–	Sell	-982	Closed	-$4.89K	–	13724
2025 Q1	$4.89K	Buy	+982	New	+$7.83K	﹤0.01%	13856
2024 Q1	–	Sell	-660	Closed	-$27.3K	–	14995
2023 Q4	$27.3K	Buy	+660	New	+$21.1K	﹤0.01%	12342
2023 Q3	–	Sell	-1,924	Closed	-$88.9K	–	14662
2023 Q2	$88.9K	Buy	+1,924	New	+$120K	﹤0.01%	11101

Other funds holding INAB

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Citadel Advisors's INAB Position: Q2 2026 in Review

Citadel Advisors opened a new position in IN8bio (INAB) in Q2 2026: 63,055 shares worth $88.9K. The stake represents ﹤0.01% of the portfolio and ranks #12776 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in INAB as recently as Q3 2025.

Citadel Advisors first reported a position in INAB in Q2 2023 and has held it in 5 quarters since. 21 funds tracked by Wall St. Rank hold INAB as of Q2 2026.

Citadel Advisors held 63,055 shares of IN8bio worth $88.9K as of Q2 2026.
IN8bio was a new Citadel Advisors position in Q2 2026.
IN8bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12776 holding.
Citadel Advisors first reported a position in IN8bio in Q2 2023 and has held it in 5 quarters since.
21 funds tracked by Wall St. Rank held IN8bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.